CM19XA: A Novel Cancer Treatment Biologic ID: 2021-052

CM19XA is an innovative biologic designed to target and inhibit cancer cell metastasis while enhancing the efficacy of CAR-T cell therapy.

Technology Overview

CM19XA is a groundbreaking cancer treatment biologic that incorporates a pH-Low Insertion Peptide (pHLIP) for targeting acidic cancer cell environments, Junctional Adhesion Molecule-A (JAM-A) to reduce cell proliferation and metastasis, and an extracellular CD19 epitope to facilitate targeted destruction by Anti-CD19 CAR-T cells. This tri-component approach addresses the limitations of traditional therapies by offering a targeted, effective method for combating cancer cell growth and spread.

Key Advantages

• Targets the acidic environment of cancer cells for precise delivery
• Reduces cancer cell proliferation and inhibits metastasis through enhanced cell-to-cell interactions
• Facilitates targeted destruction of cancer cells by CAR-T cells
• Modular design allows customization for different tumor types

Problems Addressed

• Limitations of traditional cancer therapies in targeting and inhibiting metastasis
• Need for a more effective method to enhance the efficacy of CAR-T cell therapy against cancer cells
• Challenges in creating a versatile cancer treatment capable of adapting to various tumor types

Market Applications

• Advanced cancer therapies and treatment regimens
• Customizable biologic treatments for various types of cancer
• Complementary technology for enhancing CAR-T cell therapy effectiveness
• Pharmaceutical production of novel biologics for oncology

Additional Information

Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025